Certara.AI: Real World Applications

A pharmaceutical company receives large volumes of unstructured documents from CROs, partners and departments across the organization that hold valuable data related to product attributes and the manufacturing life cycle. Manually analyzing these documents requires 2+ employees and 1+ full day of work per project, impacting over 200 total days of productivity per year.

By deploying Certara.AI, the customer has reduced time spent on data transformation and data integrity tasks, allowing them to complete these workflows in minutes vs. days. This is solution is enabled by:

• Creating a single source for searching for documents
• Automating the data extraction process 
• Reducing data integrity reviews by removing the need to manually transform data
• Enabling broad use of research and extraction capabilities for non-technical individuals through intuitive applications

With a more productive team, the pharmaceutical company is accelerating the review of compound analyses enabling more efficient product development by enabling better yields and less loss.

A global pharmaceutical company is developing a database of drug targets. To date this database is built off of manually research and data collection which requires a full time-dedicated team. Once this data is collected, there is no mechanism for them to validate their findings which reduces value and insight delivery to internal pharmacologists.

Certara.AI provides the pharma with a platform for applying AI to this process, reducing manual research tasks and providing rich context needed to understand the targets being investigated in their drug development process. This is achieved through:​

• AI-powered natural language question-answering​
• The ability to simultaneously search against internal and publicly available literature​
• Providing references that can be exported to accompany pharma’s internal database

Global Pharmaceutical company wanted a single platform for managing, accessing, analyzing and manipulating clinical outcomes meta-analysis data. ​

By integrating Certara.AI’s data fabric and GPT literature search into CODEX we were able to provide a compelling solution – a comprehensive platform for collecting, managing and updating clinical outcomes datasets for trial design, benchmarking and market intelligence.

CODEX  presents a paradigm shift in how the industry approach clinical trial analysis shifting from just datasets to a fully integrated software solution that combines the best of Certara’s CDDS data services with innovative technology. ​

With the CODEX the customer can:

• Improve data access to clinical outcomes data​
• Digitize their meta-analyses​
• Apply AI to new literature sources allowing them to dynamically update their datasets​
• Cross reference data across indications​
• Gain new visualization from data not procured by Certara. We become the home of all clinical outcomes data. ​

Global pharmaceutical’s medical affairs team currently invests ~$50k/month to have a vendor aggregate, read, and summarize literature relevant to their drugs. 

These reports are delivered as stagnant PowerPoint documents that often miss data, have mistakes and do not allow pharma company to have access to the most recent insights on their key therapeutic areas.

Signal provides pharma company’s medical affairs team with the ability to track trends specific to therapeutic areas, treatments, key opinion leaders and more to inform market/competitive intelligence. 

Certara.AI has become a trusted AI partner of a US federal agency over the past 2+ years of partnership. 

Program began with leveraging Certara.AI’s Curate tool for analyzing unstructured call transcripts. As the world of AI has evolved over the last two years, the federal agnecy has approached Certara.AI with new ideas – all of which we’ve been able to deliver on. 

Certara.AI’s flexible deployment has made us a go-to solution provider within the federal agency and has allowed us to build a promising federal business unit by providing

• Secure, air-gapped AI software
• Private GPTs without access to external APIs
• Transmitter data proxy for auditing data movement